A Nomogram to Predict Nodal Response after Induction Chemotherapy for Hypopharyngeal Carcinoma

For hypopharyngeal carcinoma, metastatic neck nodes with a low response to induction chemotherapy (ICT) should not be managed with concomitant chemoradiotherapy (CCRT), and the prediction of chemosensitivity before ICT could prevent adverse events from occurring during chemotherapy. In this study, we developed a nomogram to predict the regional response to ICT.

[1]  F. Ouyang,et al.  A Nomogram for Pretreatment Prediction of Response to Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma , 2020, Frontiers in Oncology.

[2]  Selçuk Güneş,et al.  Prognostic importance of harvested lymph node number, metastatic lymph node number, and lymph node ratio in surgically managed laryngeal squamous cell carcinoma , 2020, Brazilian Journal of Otorhinolaryngology.

[3]  S. Morrison,et al.  Lymph protects metastasizing melanoma cells from ferroptosis , 2020, Nature.

[4]  L. Della Vecchia,et al.  Metastatic disease in head & neck oncology , 2020, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[5]  F. Bidault,et al.  Anemia and neutrophil‐to‐lymphocyte ratio in laryngeal cancer treated with induction chemotherapy , 2020, The Laryngoscope.

[6]  Yaoh-Shiang Lin,et al.  Platelet-lymphocyte and neutrophil-lymphocyte ratios: predictive factors of response and toxicity for docetaxel-combined induction chemotherapy in advanced head and neck cancers. , 2019, Journal of the Chinese Medical Association : JCMA.

[7]  Yi-bin Xi,et al.  MRI-based radiomics nomogram may predict the response to induction chemotherapy and survival in locally advanced nasopharyngeal carcinoma , 2019, European Radiology.

[8]  W. Wen,et al.  Peripheral Inflammation Markers of Chemosensitivity to Induction Chemotherapy in Hypopharyngeal Cancer Patients , 2019, ORL.

[9]  P. Delaere,et al.  Primary Treatment of T1-T2 Hypopharyngeal Cancer: Changing Paradigms. , 2019, Advances in oto-rhino-laryngology.

[10]  K. Chufal,et al.  Nodal volume as a prognostic factor in locally advanced head and neck cancer: Identifying candidates for elective neck dissection after chemoradiation with IGRT from a single institutional prospective series from the Indian subcontinent. , 2018, Oral oncology.

[11]  B. Miles,et al.  Hypopharyngeal cancer: A state of the art review. , 2018, Oral oncology.

[12]  H. Ying,et al.  Impact of tumor dimensions and lymph node density on the survival of patients with hypopharyngeal squamous cell carcinoma , 2018, Cancer management and research.

[13]  Jonathan R. Clark,et al.  Lymph node ratio as a prognostic factor in metastatic cutaneous head and neck squamous cell carcinoma , 2018, Head & neck.

[14]  S. O'Leary,et al.  Predictors of health-related quality of life in patients treated with neck dissection for head and neck cancer , 2017, European Archives of Oto-Rhino-Laryngology.

[15]  P. Fournel,et al.  Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. , 2016, American journal of clinical pathology.

[16]  W. Guo,et al.  Pretreatment Intra-Voxel Incoherent Motion Diffusion-Weighted Imaging (IVIM-DWI) in Predicting Induction Chemotherapy Response in Locally Advanced Hypopharyngeal Carcinoma , 2016, Medicine.

[17]  Hideaki Takahashi,et al.  Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy , 2016, International Journal of Clinical Oncology.

[18]  Wenjie Zhu,et al.  Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study , 2015, PloS one.

[19]  Y. Hasegawa,et al.  The nodal response to chemoselection predicts the risk of recurrence following definitive chemoradiotherapy for pharyngeal cancer , 2014, Acta oto-laryngologica.

[20]  Pierre Blanchard,et al.  Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Tishler,et al.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. , 2011, The Lancet. Oncology.

[22]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[24]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[25]  L. Harrison,et al.  Planned Neck Dissection after Concomitant Radiochemotherapy for Advanced Head and Neck Cancer , 2005, The Laryngoscope.

[26]  D. Generali,et al.  Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer , 2003, British Journal of Cancer.

[27]  M. Quer,et al.  Treatment of neck nodes after induction chemotherapy in patients with primary advanced tumours , 2000, European Archives of Oto-Rhino-Laryngology.

[28]  J. Sham,et al.  Evaluation of cervical nodal necrosis in nasopharyngeal carcinoma by computed tomography: Incidence and prognostic significance , 1997, Head & neck.

[29]  S. Fisher,et al.  Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation , 1992, The Laryngoscope.